Active	Status	Sponsor type	Region	Phase	Filter
1 Active 22 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
vadimezan (ASA404) / Antisoma
2009-016834-28: An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials	Ongoing	4		Europe	ASA404, ASA404,	Novartis Pharma Services AG	Solid tumors
BTH1704 / HiberCell
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
vadimezan (ASA404) / Antisoma
2009-016834-28: An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials	Ongoing	4		Europe	ASA404, ASA404,	Novartis Pharma Services AG	Solid tumors
BTH1704 / HiberCell
No trials found